StreetInsider.com News Articles

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.02 per share, which is

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

The options have an exercise price of $1.02 per share, which is

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

The options have an exercise price of $1.02 per share, which is

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

The options have an exercise price of $1.02 per share, which is

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast

Form SCHEDULE 13G Akebia Therapeutics, Filed by: STATE STREET CORP

Tue, 12 May 2026 09:45:00 -0400

si-local-file:///var/storage/secattach/20260512/26474839.html

Form SCHEDULE 13G Akebia Therapeutics, Filed by: STATE STREET CORP

Tue, 12 May 2026 09:45:00 -0400

si-local-file:///var/storage/secattach/20260512/26474839.html

Form 10-Q Akebia Therapeutics, For: Mar 31

Thu, 07 May 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26448219.html

Form 10-Q Akebia Therapeutics, For: Mar 31

Thu, 07 May 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26448219.html

Akebia Therapeutics (AKBA) Misses Q1 EPS by 2c

Thu, 07 May 2026 07:08:53 -0400

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $53.54 million versus the consensus estimate of $54.89 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

Form 8-K Akebia Therapeutics, For: May 07

Thu, 07 May 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260507/26447987.html

Form 8-K Akebia Therapeutics, For: May 07

Thu, 07 May 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260507/26447987.html

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Thu, 07 May 2026 07:00:00 -0400

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million

Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025

Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts

Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS)

Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST

CAMBRIDGE, Mass., May